LDC has sold drug-research company Synexus to Jaguar Holding in a deal that values Synexus at £178 million; LDC generated a 2.3x money multiple through the transaction, exiting an £83 million investment from March 2015. The company provides patient-recruitment and treatment services in support of drug research for clinical trials, operating a network of 92 research centers around the globe.
Worldwide, PE investor activity in the pharmaceuticals and biotechnology space has been on a gradual rise since 2010, rebounding from a 31% dip that occurred in the wake of the financial crisis. PE firms completed 111 deals in the sector last year after executing 113 in 2014, according to the PitchBook Platform. Deal count for 2016 currently sits at 39, with 51% of that activity taking place in the U.S. (the highest proportion since 2009) and another 36% in Europe.
Here are the most active PE firms in pharma & biotech since 2006, along with their deal counts (incl. add-ons):